TY  - JOUR
A1  - Havik, Bjarte
A1  - Degenhardt, Franziska A.
A1  - Johansson, Stefan
A1  - Fernandes, Carla P. D.
A1  - Hinney, Anke
A1  - Scherag, André
A1  - Lybaek, Helle
A1  - Djurovic, Srdjan
A1  - Christoforou, Andrea
A1  - Ersland, Kari M.
A1  - Giddaluru, Sudheer
A1  - O'Donovan, Michael C.
A1  - Owen, Michael J.
A1  - Craddock, Nick
A1  - Mühleisen, Thomas W.
A1  - Mattheisen, Manuel
A1  - Schimmelmann, Benno G.
A1  - Renner, Tobias
A1  - Warnke, Andreas
A1  - Herpertz-Dahlmann, Beate
A1  - Sinzig, Judith
A1  - Albayrak, Özgür
A1  - Rietschel, Marcella
A1  - Nöthen, Markus M.
A1  - Bramham, Clive R.
A1  - Werge, Thomas
A1  - Hebebrand, Johannes
A1  - Haavik, Jan
A1  - Andreassen, Ole A.
A1  - Cichon, Sven
A1  - Steen, Vidar M.
A1  - Le Hellard, Stephanie
T1  - DCLK1 Variants Are Associated across Schizophrenia and Attention Deficit/Hyperactivity Disorder
JF  - PLoS One
N2  - Doublecortin and calmodulin like kinase 1 (DCLK1) is implicated in synaptic plasticity and neurodevelopment. Genetic variants in DCLK1 are associated with cognitive traits, specifically verbal memory and general cognition. We investigated the role of DCLK1 variants in three psychiatric disorders that have neuro-cognitive dysfunctions: schizophrenia (SCZ), bipolar affective disorder (BP) and attention deficit/hyperactivity disorder (ADHD). We mined six genome wide association studies (GWASs) that were available publically or through collaboration; three for BP, two for SCZ and one for ADHD. We also genotyped the DCLK1 region in additional samples of cases with SCZ, BP or ADHD and controls that had not been whole-genome typed. In total, 9895 subjects were analysed, including 5308 normal controls and 4,587 patients (1,125 with SCZ, 2,496 with BP and 966 with ADHD). Several DCLK1 variants were associated with disease phenotypes in the different samples. The main effect was observed for rs7989807 in intron 3, which was strongly associated with SCZ alone and even more so when cases with SCZ and ADHD were combined (P-value = 4x10\(^{-5}\) and 4x10\(^{-6}\), respectively). Associations were also observed with additional markers in intron 3 (combination of SCZ, ADHD and BP), intron 19 (SCZ+BP) and the 3'UTR (SCZ+BP). Our results suggest that genetic variants in DCLK1 are associated with SCZ and, to a lesser extent, with ADHD and BP. Interestingly the association is strongest when SCZ and ADHD are considered together, suggesting common genetic susceptibility. Given that DCLK1 variants were previously found to be associated with cognitive traits, these results are consistent with the role of DCLK1 in neurodevelopment and synaptic plasticity.
KW  - psychosis
KW  - deficit hyperactivity disorder
KW  - genome-wide association
KW  - bipolar disorder
KW  - VAL66MET polymorphism
KW  - doublecortine-like
KW  - genes
KW  - kinase
KW  - BDNF
KW  - endophenotype
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-135285
VL  - 7
IS  - 4
ER  - 
TY  - JOUR
A1  - Hennings, Johannes M.
A1  - Kohli, Martin A.
A1  - Czamara, Darina
A1  - Giese, Maria
A1  - Eckert, Anne
A1  - Wolf, Christiane
A1  - Heck, Angela
A1  - Domschke, Katharina
A1  - Arolt, Volker
A1  - Baune, Bernhard T.
A1  - Horstmann, Sonja
A1  - Brückl, Tanja
A1  - Klengel, Torsten
A1  - Menke, Andreas
A1  - Müller-Myhsok, Bertram
A1  - Ising, Marcus
A1  - Uhr, Manfred
A1  - Lucae, Susanne
T1  - Possible Associations of NTRK2 Polymorphisms with Antidepressant Treatment Outcome: Findings from an Extended Tag SNP Approach
JF  - PLoS ONE
N2  - Background: Data from clinical studies and results from animal models suggest an involvement of the neurotrophin system in the pathology of depression and antidepressant treatment response. Genetic variations within the genes coding for the brain-derived neurotrophic factor (BDNF) and its key receptor Trkb (NTRK2) may therefore influence the response to antidepressant treatment.
Methods: We performed a single and multi-marker association study with antidepressant treatment outcome in 398 depressed Caucasian inpatients participating in the Munich Antidepressant Response Signature (MARS) project. Two Caucasian replication samples (N = 249 and N = 247) were investigated, resulting in a total number of 894 patients. 18 tagging SNPs in the BDNF gene region and 64 tagging SNPs in the NTRK2 gene region were genotyped in the discovery sample; 16 nominally associated SNPs were tested in two replication samples.
Results: In the discovery analysis, 7 BDNF SNPs and 9 NTRK2 SNPs were nominally associated with treatment response. Three NTRK2 SNPs (rs10868223, rs1659412 and rs11140778) also showed associations in at least one replication sample and in the combined sample with the same direction of effects (\(P_{corr}\) = .018, \(P_{corr}\) = .015 and \(P_{corr}\) = .004, respectively). We observed an across-gene BDNF-NTRK2 SNP interaction for rs4923468 and rs1387926. No robust interaction of associated SNPs was found in an analysis of BDNF serum protein levels as a predictor for treatment outcome in a subset of 93 patients.
Conclusions/Limitations: Although not all associations in the discovery analysis could be unambiguously replicated, the findings of the present study identified single nucleotide variations in the BDNF and NTRK2 genes that might be involved in antidepressant treatment outcome and that have not been previously reported in this context. These new variants need further validation in future association studies.
KW  - brain
KW  - bipolar disorder
KW  - mood disorder
KW  - treatment response
KW  - genome-wide association
KW  - major depressive disorder
KW  - neurotrophic factor gene
KW  - VAL66MET polymorphism
KW  - sequence variations
KW  - messenger RNA
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130924
VL  - 8
IS  - 6
ER  -